Inferring tumour purity and stromal and immune cell admixture from expression data

Nature Communications

Volumn 4, Issue , 2013, Pages

  Yoshihara, Kosuke ^a,b   Shahmoradgoli, Maria ^a   Martínez, Emmanuel ^a,c   Vegesna, Rahulsimham ^a   Kim, Hoon ^a   Torres Garcia, Wandaliz ^a   Treviño, Victor ^c   Shen, Hui ^d   Laird, Peter W ^d   Levine, Douglas A ^e   Carter, Scott L ^f   Getz, Gad ^f   Stemke Hale, Katherine ^a   Mills, Gordon B ^a   Verhaak, Roel G W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB;

CANCER; CYTOLOGY; GENE EXPRESSION; GENETIC ANALYSIS; GENOME; IMMUNE SYSTEM; MOLECULAR ANALYSIS; TUMOR;

ALGORITHM; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CELL ADHESION; CELL FRACTIONATION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENOMICS; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; LASER CAPTURE MICRODISSECTION; LEUKOCYTE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; METHYLATION; NUCLEIC ACID BASE SUBSTITUTION; OVARY CARCINOMA; PREDICTIVE VALUE; RNA SEQUENCE; SOMATIC MUTATION; STROMA; STROMA CELL; TRANSCRIPTOMICS; TUMOR CELL;

ALGORITHMS; CELL SEPARATION; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENE LIBRARY; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKOCYTES; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; SOFTWARE; STROMAL CELLS; TRANSCRIPTOME;

EID: 84885673911     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3612     Document Type: Article

References (69)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392-401 (2006).
3. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
4. Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
5. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003). (Pubitemid 36077915)
6. Sato, E. et al. Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102, 18538-18543 (2005). (Pubitemid 43011261)
7. Pages, F. et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654-2666 (2005). (Pubitemid 41817714)
8. Mlecnik, B. et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29, 610-618 (2011).
9. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002). (Pubitemid 35461656)
10. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005). (Pubitemid 41528150)
11. Director's Challenge Consortium for the Molecular Classification of lung adenocarcinoma. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med. 14, 822-827 (2008).
12. Verhaak, R. G. et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94, 131-134 (2009).
13. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
14. Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910-16915 (2010).
15. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
16. de Ridder, D. et al. Purity for clarity: the need for purification of tumor cells in DNA microarray studies. Leukemia 19, 618-627 (2005).
17. Su, X., Zhang, L., Zhang, J., Meric-Bernstam, F. & Weinstein, J. N. PurityEst: estimating purity of human tumor samples using next-generation sequencing data. Bioinformatics 28, 2265-2266 (2012).
18. Venet, D., Pecasse, F., Maenhaut, C. & Bersini, H. Separation of samples into their constituents using gene expression data. Bioinformatics 17(Suppl 1): S279-S287 (2001). (Pubitemid 33793520)
19. Erkkila, T. et al. Probabilistic analysis of gene expression measurements from heterogeneous tissues. Bioinformatics 26, 2571-2577 (2010).
20. Shen-Orr, S. S. et al. Cell type-specific gene expression differences in complex tissues. Nat. Methods 7, 287-289 (2010).
21. Shoemaker, J. E. et al. CTen: a web-based platform for identifying enriched cell types from heterogeneous microarray data. BMC Genomics 13, 460 (2012).
22. Bolen, C. R., Uduman, M. & Kleinstein, S. H. Cell subset prediction for blood genomic studies. BMC Bioinformatics 12, 258 (2011).
23. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
24. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
25. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
26. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
27. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
28. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
29. The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
30. Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198-5208 (2008).
31. Ma, X. J., Dahiya, S., Richardson, E., Erlander, M. & Sgroi, D. C. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 11, R7 (2009).
32. Nishida, N. et al. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin. Cancer Res. 18, 3054-3070 (2012).
33. Munz, M., Baeuerle, P. A. & Gires, O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 69, 5627-5629 (2009).
34. Robin, X. et al. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).
35. Yao, M. et al. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol. 205, 377-387 (2005). (Pubitemid 40253927)
36. Mueller, E. et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell 1, 465-470 (1998). (Pubitemid 128378895)
37. Verhaak, R. G. et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123, 517-525 (2013).
38. Grabmaier, K. et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int. J. Cancer 85, 865-870 (2000). (Pubitemid 30131479)
39. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
40. Lynch, T. J. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30, 2046-2054 (2012).
41. Cohen, D. A. et al. Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. Am. J. Clin. Pathol. 138, 796-802 (2012).
42. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
43. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428 (2009).
44. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
45. The Cancer Genome Atlas Data Portal https://tcga-data.nci.nih.gov/tcga/.
46. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621-628 (2008). (Pubitemid 351911867)
47. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
48. Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207-210 (2002). (Pubitemid 34679544)
49. Rustici, G. et al. ArrayExpress update-trends in database growth and links to data analysis tools. Nucleic Acids Res. 41(Database issue): D987-D990 (2013).
50. NCI. REMBRANDT http://rembrandt.nci.nih.gov.
51. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
52. Liu, H. et al. AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics 23, 2385-2390 (2007). (Pubitemid 47423835)
53. Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
54. Yoshihara, K. et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin. Cancer Res. 18, 1374-1385 (2012).
55. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001). (Pubitemid 32397092)
56. TCGA ovarian cancer unified expression data http://tcga-data.nci.nih.gov/ docs/publications/unified-expression/(2010).
57. Rosner, B. Percentage points for genralized ESD many-outlier procedure. Technometrics 25, 165-172 (1983). (Pubitemid 13540616)
58. Caroni, C. & Prescott, P. Sequential application of Wilks's multivariate outlier test. Appl. Stat. 41, 355-364 (1992).
59. Eureqa http://creativemachines.cornell.edu/eureqa (2000).
60. Schmidt, M. & Lipson, H. Distilling free-form natural laws from experimental data. Science 324, 81-85 (2009).
61. ABSOLUTE https://confluence.broadinstitute.org/display/CGATools/ABSOLUTE (2013).
62. Affymetrix Power Tools http://www.affymetrix.com/partners-programs/ programs/developer/tools/powertools.affx (2013).
63. Adachi, S. et al. Meta-analysis of genome-wide association scans for genetic susceptibility to endometriosis in Japanese population. J. Hum. Genet. 55, 816-821 (2010).
64. Synapse BETA https://www.synapse.org/(2013).
65. Dees, N. D. et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. (2012; 22, 1589-1598.
66. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994-1007 (2012).
67. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
68. R Development Core Team. R: a language and environment for statistical computing (2011).
69. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B Met. 57, 289-300 (1995).